Alvotech and Advanz Pharma's Milestone with AVT05
Recently, Alvotech, a pioneering biotech firm known for its expertise in developing biosimilar medicines, was excited to announce a significant advancement in their product offering. Together with Advanz Pharma, a prominent name in specialty pharmaceuticals, they revealed that the European Medicines Agency (EMA) has accepted their Marketing Authorization Application for AVT05. This proposed biosimilar to Simponi (golimumab), a biologic instrumental in treating numerous chronic inflammatory diseases, marks an important milestone for both companies.
AVT05: A New Hope for Patients
The acceptance of AVT05 is particularly noteworthy as it heralds what could be the first marketing authorization application for a biosimilar candidate in the global market for Simponi. Joseph McClellan, Chief Scientific Officer of Alvotech, expressed enthusiasm regarding this development. He stated that this brings them one step closer to providing a valuable treatment option for patients, their caregivers, and those involved in their healthcare. Alvotech's ability to utilize a process similar to that used for the reference biologic has played a vital role in the development of AVT05.
The Implications for Treatment Access
Nick Warwick, the Chief Medical Officer of Advanz Pharma, emphasized the importance of this application acceptance. He noted that this represents a substantial advancement in broadening treatment options for individuals suffering from chronic inflammatory diseases across Europe. Their goal is to improve the accessibility of high-quality biologic medicines to patients who need them the most.
Partnership for Growth
In February 2023, during the early stages of their collaboration, Alvotech and Advanz Pharma solidified their partnership with a commercialization agreement for AVT23, another promising biosimilar candidate targeted at Xolair (omalizumab). The partnership's initiatives were further expanded when they agreed to include five additional biosimilar candidates developed by Alvotech, including AVT05 and AVT16, which targets Entyvio (vedolizumab), alongside three additional undisclosed early-stage candidates.
Clinical Developments and Future Plans
Alvotech recently celebrated positive results from a key clinical study that compared the efficiency, safety, and immunogenicity of AVT05 and Simponi in patients diagnosed with moderate to severe rheumatoid arthritis. In addition to this, they highlighted recent advancements from a pharmacokinetic study conducted in November, showcasing the safety and tolerability of AVT05 among healthy adult participants.
Understanding the Candidates
AVT05 is a promising biosimilar candidate structured to provide an alternative for patients currently using Simponi. The treatment aims to mitigate elevated levels of tumor necrosis factor alpha (TNF alpha), which have been linked to chronic inflammatory conditions like rheumatoid arthritis. Importantly, AVT05 remains an investigational product currently waiting for regulatory approvals around the world, with no claims of biosimilarity established yet.
Another candidate, AVT16, has been poised as a biosimilar to Entyvio, manifesting similar investigational status. Meanwhile, AVT23, aiming to provide an alternative to Xolair, is also subject to ongoing clinical evaluations.
About Alvotech and Advanz Pharma
Founded by Robert Wessman, Alvotech is steadfast in its mission to lead the global biosimilars market by delivering cost-effective, high-quality biosimilar drugs. With an impressive pipeline focus including treatments for autoimmune disorders and cancer, Alvotech prioritizes extensive clinical research and has formed strategic alliances with numerous commercial partners worldwide. These affiliations bolster their marketing reach across various regions including the United States, Europe, and Asia.
On the other hand, Advanz Pharma is recognized for its commitment to enhancing patient outcomes through specialty, hospital, and rare disease medicines. The company aims to expand its commercial presence by partnering with biopharma organizations, tapping into a broad spectrum of therapeutic areas.
Frequently Asked Questions
What is AVT05?
AVT05 is a proposed biosimilar to Simponi (golimumab) formulated to treat chronic inflammatory diseases.
Which companies are involved in the AVT05 development?
Alvotech and Advanz Pharma are the companies collaborating to develop AVT05.
What regulatory body accepted the application for AVT05?
The European Medicines Agency (EMA) accepted the Marketing Authorization Application for AVT05.
What diseases does AVT05 aim to treat?
AVT05 is intended for treatment in conditions like rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Is AVT05 already approved for use?
No, AVT05 is still an investigational product and has not yet received regulatory approval.
